Lack of Benefit of Fluvoxamine for COVID-19

被引：5
作者：
Bhimraj, Adarsh [1 ,3 ]
Gallagher, Jason C. [2 ]
机构：
[1] Houston Methodist Hosp, Div Infect Dis, Houston, TX USA
[2] Temple Univ, Dept Pharm Practice, Philadelphia, PA USA
[3] Houston Methodist Hosp, Infect Dis Fellowship & Educ, 6560 Fannin St, Ste 1512, Houston, TX 77030 USA
来源：
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION | 2023年 / 329卷 / 04期
关键词：
D O I：
10.1001/jama.2022.23954
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：291 / 292
页数：2
相关论文
共 50 条
[21]   Fluvoxamine for outpatients with COVID-19: where do we stand? [J].
Berwanger, Otavio .
LANCET GLOBAL HEALTH, 2022, 10 (01) :E2-E3
[22]   Lack of efficacy of hydroxychloroquine in covid-19 [J].
Vinetz, Joseph M. .
BMJ-BRITISH MEDICAL JOURNAL, 2020, 369
[23]   Therapeutic potential of fluvoxamine in COVID-19 outpatients: a case report [J].
Rudez, Lorena Karla ;
Sklebar, Tin ;
Calusic, Martina ;
Jurkovic, Ivan ;
Kirsch, Steven ;
Likic, Robert .
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2021, 87 (12) :4880-4881
[24]   Fluvoxamine for non-hospitalized patients affected with COVID-19 [J].
Wu, Peter E. ;
Austin, Emily ;
Leong, Derek .
CANADIAN MEDICAL ASSOCIATION JOURNAL, 2022, 194 (11) :E437-E438
[25]   Elections and COVID-19 benefit payments [J].
Bessho, S. .
JOURNAL OF ASIAN ECONOMICS, 2023, 87
[26]   COVID-19 benefit from statins? [J].
Devi, Sharmila .
LANCET INFECTIOUS DISEASES, 2021, 21 (04) :467-467
[27]   Potential Role of the Antidepressants Fluoxetine and Fluvoxamine in the Treatment of COVID-19 [J].
Mahdi, Mohamed ;
Herman, Levente ;
Rethelyi, Janos M. ;
Balint, Balint Laszlo .
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2022, 23 (07)
[28]   Why we should not recommend or offer fluvoxamine to COVID-19 patients? [J].
Trkulja, Vladimir .
EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 2023, 79 (02) :321-322
[29]   Why we should not recommend or offer fluvoxamine to COVID-19 patients? [J].
Vladimir Trkulja .
European Journal of Clinical Pharmacology, 2023, 79 :321-322
[30]   Heme oxygenase agonists—fluvoxamine, melatonin—are efficacious therapy for Covid-19 [J].
Philip L. Hooper .
Cell Stress and Chaperones, 2022, 27 :3-4
12345